SD-OCT Measurement of the Human Retina in Pregnancy With Pre-existing or De Novo Hypertension and Without Hypertension
NCT ID: NCT04286217
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
155 participants
OBSERVATIONAL
2013-10-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microcirculatory and Tissue and Cerebral Oxygenation in Preeclampsia and Normal Pregnancy: An Observation Study
NCT02351583
Retinal Vascular Changes During Pregnancy
NCT06311617
Identifying Biomarkers for Endothelial Dysfunction in Women With Preeclampsia
NCT07084727
The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health
NCT01888770
Hemodynamic Changes During Normal Pregnancy
NCT00682201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data was collected at enrolment (\< 20 weeks gestation), at every follow-up clinical encounter with the Foothills Hospital High-risk Obstetrical clinic between 20 weeks gestation and delivery, at delivery itself, and at least 1 additional encounter in the non-pregnant state, usually postpartum. Demographic information including participant age, gestational age, medical co-morbidities, medications, clinical symptoms, weight, height, automated office blood pressure and all investigations ordered by managing physicians were recorded. In addition, macular thickness was measured at each encounter using spectral domain optical coherence tomography (SD-OCT). Obstetrical and neonatal outcomes were collected from standardized birth and delivery records.
SD-OCT images were performed by a trained physician or research assistant according to the following standardized technique. The same Zeiss Cirrus 4000 SD-OCT instrument was used for all retinal images. Two SD-OCT images were obtained from each eye at each clinical encounter without dilation of the pupil at a scanning resolution of 512 A-scans x 128 B-scans over a 6 mm square grid focused on the fovea. Between sequential sessional measurements (i.e., right eye first measurement, right eye second measurement, etc.) participants were instructed to remove their face from the examining platform and the instrument was reset to default parameters in order to match the effect of an independent scan. Scans were examined systematically for signal strength, definition of the vessel architecture, centrality and motion artifact to determine image quality, and the better of the 2 images was prospectively selected for analysis. Macular thickness was measured from the internal limiting membrane to the retinal pigment epithelium, a standard method completed by the instrument on every retinal scan. All scans were referenced to the image obtained from the same individual in the non-pregnant state to determine interval change over the pregnancy.
Given the exploratory nature of this study and its small subject numbers, the research team considered both standard summary statistics and measures of individual response. In respect to the latter, a decision support tool was derived before starting the study whereby 'clinically meaningful change' was arbitrarily defined as a directionally identical difference ≥ ±4 µm (the test re-test coefficient of repeatability of the instrument) in 3 or more contiguous segments on the Early Treatment of Diabetic Retinopathy Study (ETDRS) grid \[1\] in a single eye. This summary measure was subsequently tested against the frequency of appearance of all possible combinations of ETDRS segments possessing that and other levels of differential change in a null difference distribution comprised of 1370 paired images collected on all participants enrolled in SD-OCT studies managed by the PI as of May 2017. This tool identifies a statistically significant interval change compared to the expected null difference at a P-value = 0.046. Assessment of this parameter is ongoing and will be published separately.
Participant characteristics were summarized by descriptive statistics using means and standard deviation (SD) for continuous variables and frequencies for categorical variables. A 95% confidence interval (95%CI) was computed for each outcome parameter. Statistical significance was defined as a P-value \<0.05. A linear mixed-effects model was used to estimate macular thickness at the 3 gestational intervals with random effects considered at three hierarchical levels: patient level, eye side (right or left) and position on the ETDRS grid. A continuous autocorrelation structure was used to adjust for correlation of variables repeatedly measured at differing clinical encounters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No prior hypertension (HTN); no HDP in pregnancy
No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
No interventions assigned to this group
No prior HTN; de novo HDP, GH type; no macular injury
No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
No interventions assigned to this group
No prior HTN; de novo HDP, GH type; macular injury found
No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
No prior HTN; de novo HDP, PE type; no macular injury
No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
No interventions assigned to this group
No prior HTN; de novo HDP, PE type; macular injury found
No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
No prior HTN; no HDP in pregnancy; postpartum HDP
No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
Pre-existing HTN; no HDP in pregnancy
Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
No interventions assigned to this group
Pre-existing HTN; de novo HDP, GH type; no macular injury
Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
No interventions assigned to this group
Pre-existing HTN; de novo HDP, GH type; macular injury found
Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
Pre-existing HTN; de novo HDP, PE type; no macular injury
Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
No interventions assigned to this group
Pre-existing HTN; de novo HDP, PE type; macular injury found
Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
Pre-existing HTN; no HDP in pregnancy; postpartum HDP
Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
No interventions assigned to this group
Other causes of macular injury leading to HDP
Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
No interventions assigned to this group
Other causes of macular injury not leading to HDP
Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Cohort II Women at High-risk for Developing an HDP
* chronic hypertension
* prior preeclampsia
* prior gestational hypertension
* chronic kidney disease, or
* ≥ 2 of the following: age \>35 years, body mass index (BMI) \> 30 kg/m2, twin or multiple gestation pregnancy, non-Caucasian ethnicity
Exclusion Criteria
* vasculitis
* known or observed retinal disease at enrolment
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert J Herman, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
References
Explore related publications, articles, or registry entries linked to this study.
Huang J, Liu X, Wu Z, Xiao H, Dustin L, Sadda S. Macular thickness measurements in normal eyes with time-domain and Fourier-domain optical coherence tomography. Retina. 2009 Jul-Aug;29(7):980-7. doi: 10.1097/IAE.0b013e3181a2c1a7.
Conti E, Zezza L, Ralli E, Caserta D, Musumeci MB, Moscarini M, Autore C, Volpe M. Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards? Cytokine Growth Factor Rev. 2013 Oct;24(5):411-25. doi: 10.1016/j.cytogfr.2013.05.008. Epub 2013 Jun 22.
Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int. 2009 Oct;76(8):831-7. doi: 10.1038/ki.2009.284. Epub 2009 Aug 5.
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014 May;36(5):416-41. doi: 10.1016/s1701-2163(15)30588-0. English, French.
Wolf M, Shah A, Jimenez-Kimble R, Sauk J, Ecker JL, Thadhani R. Differential risk of hypertensive disorders of pregnancy among Hispanic women. J Am Soc Nephrol. 2004 May;15(5):1330-8. doi: 10.1097/01.asn.0000125615.35046.59.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB15-0374
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.